
Bicycle Therapeutics develops bi-cyclic peptide medicines combining biologic-like pharmacology with small-molecule pharmacokinetics.
bicycletherapeutics.comCrawled Nov 3, 2026
Dr. Reis e Sousa heads the Immunobiology Laboratory at the Crick Institute and holds professorships at Imperial College London, University College London, and King’s College London.
Dr. FitzGerald directs the Institute for Translational Medicine and Therapeutics at the University of Pennsylvania and previously chaired its Department of Systems Pharmacology and Translational Therapeutics.
Geoffrey Shapiro leads the Early Drug Development Center and serves as clinical director of the Center for DNA Damage and Repair at Dana-Farber Cancer Institute.
Sir Keith Peters was Emeritus Regius Professor of Physics and head of the School of Clinical Medicine at the University of Cambridge.
Bicycle Therapeutics is cutting 30% of its workforce and shifting focus away from its bladder cancer therapy, **Zelenectide**, which was positioned as a competitor to Pfizer’s blockbuster drug **Padcev**. The company now projects a longer regulatory approval timeline than previously expected, prompting the strategic shift.
Bicycle Therapeutics shares 2025 progress and 2026 plans, including dose selection from the Phase 2/3 **Duravelo-2** trial and regulatory feedback expected in early 2026. The company’s **radiopharmaceuticals pipeline** advances, with planned **EphA2 human imaging data** in the first half of 2026. Early results from the Phase 1/2 **Duravelo-3** trial—testing **zelenectide pevedotin** in **NECTIN4-amplified breast cancer**—are also highlighted.
Bicycle Therapeutics reports a **60% overall response rate** for its **zelenectide pevedotin** combined with **pembrolizumab** in treating first-line metastatic urothelial cancer. The results align with current therapy benchmarks. The company also updates its development strategy, focusing on **NECTIN4 gene amplification** as a key driver in its pipeline.
Bicycle Therapeutics raises **$555 million** in a share issue, boosting its cash reserves to **$1 billion** and extending its financial runway to mid-2027. The company leverages the funds to support ongoing operations and development. The funding follows a structured capital raise closing this week.
Bicycle Therapeutics secures **$555 million** in equity financing through a private placement. The Cambridge-based medtech company focuses on developing therapies aimed at preventing diseases. The funding round highlights strong investor confidence in its approach to disease prevention.